Fibroadenomas are the most common benign tumors of the female breast and are associated with a slight increase in the risk of subsequent breast cancer. Multiple fibroadenomas have been described in patients after renal transplantation and are thought to be secondary to drug-related growth stimulation. Epstein-Barr virus (EBV) has been detected in many neoplasms, including breast cancer. We set out to investigate whether EBV plays a role in the development of rapidly growing fibroadenomas in immunocompromised patients. We studied 19 fibroadenomas and one invasive ductal carcinoma that developed after organ transplantation or treatment for lupus erythematosus. As a control group we included 11 fibroadenomas from non-immunocompromised patients. DNA was amplified using polymerase chain reaction (PCR) of the EBV-encoded small RNA (EBER-2) DNA sequence. EBV latent membrane protein 1 (LMP-1) transcripts were amplified using reverse transcription (RT) PCR. Immunohistochemical (IHC) staining for LMP-1 protein was performed. A total of 9 out of 20 tumors (45%) were concordantly positive by PCR and IHC. IHC stained exclusively the epithelial cells. All the fibroadenomas in non-immunocompromised patients were negative for LMP-1 (Fisher's exact test P ‫؍‬ .0006). These data suggest that EBV is associated with fibroadenomas in this immunosuppressed population and that the infection is specifically localized to epithelial cells. This is the first study suggesting a role for EBV in the pathogenesis of fibroadenomas. 
Epstein-Barr virus (EBV) is a common human
␥-herpes virus estimated to have infected about 95% of the adult population worldwide. Despite the widespread prevalence of EBV infection, EBV has been directly implicated in the development of only two malignancies observed in relatively restricted geographic areas: Burkitt's Lymphoma in East Africa and nasopharyngeal carcinoma in Southern China. It has also been closely associated to Hodgkin's Disease, thymic lymphoepithelioma, opportunistic B-cell lymphomas, pleural B-cell lymphomas or pyothorax associated B-cell lymphomas, opportunistic T-cell and NK-cell lymphomas in immunodeficiencies, primary nasal T-cell and NK-cell lymphomas, gastric carcinoma, and most recently, invasive breast carcinoma (1) (2) (3) (4) (5) (6) (7) (8) (9) .
As the number of possible associations between ␥-herpes viruses and human cancer continues to grow, the question of whether the individual's immune-response status is a predisposing factor for virally mediated neoplasms emerges. Patients with suppressed immune systems from HIV infection or post-organ transplant immunosuppressive drugs are important groups in whom to study viral carcinogenesis. Kaposi sarcoma, now known to be caused by human herpes virus-8 (HHV-8), is an AIDS-defining malignancy (10) . Forty to 66% of transplant patients develop skin cancer within 20 years of the transplant procedure, presumably because cellular immunosuppression provides an opportunistic environment for cancer-associated vi-ruses (11) . EBV-positive B-cell lymphomas are also present in about 20 -30% of AIDS patients (12) .
Fibroadenomas are benign breast tumors that have been associated with a slight increased risk of breast cancer (13, 14) . The observation of rapidly growing fibroadenomas in immunosuppressed patients suggests a possible viral cofactor in the pathogenesis of benign breast neoplasms. In this study, we set out to test the hypothesis that EBV plays a role in the development of fibroadenomas in immunocompromised patients.
MATERIALS AND METHODS

Patient Sample Selection
Twenty patients with rapidly growing tumors of the breast were identified. The identification of rapidly growing was performed using mammographic evaluation. All the patients had masses growing faster than expected on mammograms from year to year. As controls, identified a group of 11 fibroadenomas in non-immunosuppressed patients. The formalin-fixed, paraffin-embedded breast tissues were retrieved from the Pathology files at the University of Michigan. The cases included 19 fibroadenomas and one invasive ductal carcinoma. Tissues were obtained by core biopsy (three cases) or by open biopsy (17 cases). All patients were either taking immunosuppressive drugs to prevent organ graft rejection or to control systemic lupus erythematosus. After selection, the tissues were stripped of identifiers referable to the patients.
DNA Extraction
Blocks were cut into sections and mounted on glass slides for analysis. Laser capture microdissection (LCM) technique was used for DNA extraction as previously described (15) . Paraffin sections were deparaffinized, dehydrated, and stained with eosin. Individual tumor epithelial cells were microdissected off each section using a PixCell II LCM system (Arcturus, Mountain View, CA). Laser pulses were used to fuse individual cells onto the surface of transfer film/microcentrifuge tube caps. Digestion buffer (0.04% Proteinase K, 10 mM Tris-HCL (pH 8.0), 1 mM EDTA, and 1% Tween-20) was added to the tubes. The capped tubes were inverted and incubated overnight at 37°C. Samples were boiled for 5 minutes at 95°C and, if not used immediately, stored at Ϫ20°C. As positive control we used DNA from a known EBV-positive testicular lymphoma.
PCR Amplification
Primers for the EBV-encoded small RNA (EBER-2) DNA sequence were synthesized as previously described (5'-CCCTAGTGGTTTCGGACACA-3' sense primer and 5'-ACTTGCAAATGCTCTAGGCG-3' antisense primer) (2) . PCR reagents and reaction protocols were tested using pilot runs with DNA extracted from an EBV-positive testicular lymphoma. Singleround PCR of our LCM-extracted tumor DNA (15 L) were then performed using the following conditions: denaturation at 95°C (5 minutes), followed by 40 cycles of denaturation at 95°C (30 seconds), annealing at 58°C (1 minute), and extension at 72°C (2 minutes). The cycle was followed by a 7 minute extension at 72°C.
To determine whether the extracted DNA was technically suitable for PCR amplification, a region of the beta-tubulin gene sequence was concurrently amplified (5'-AAATTTTAACCATGAGGGAAA-TC-3' sense primer and 5'-GTGGGGTCGATGCCAT-GT-3' anti-sense primer). Single-round PCR was performed as follows: denaturation at 95°C (5 minutes), followed by 35 cycles of denaturation at 95°C (1 minute), annealing at 58°C (1 minute), and extension at 72°C (2 minutes), ending with a 7 minute extension at 72°C. Both EBER-2 and beta-tubulin PCR products were separated on a 2.5% agarose gel by electrophoresis and visualized with ethidium bromide under UV light.
RT-PCR Amplification
Tissue was scraped off paraffin embedded sections and onto siliconized 2.0 ml microcentrifuge tubes (Life Science Products, Denver, CO) for RNA extraction. Two slides were scraped for each sample, deparaffinized in xylene and washed in ethanol. After centrifugation at 20,800 RCF for 10 minutes, Trizol RNA isolation reagent (Life Technologies, Rockville, MD) was added to the dried pellets. Tubes were then incubated at 65°C for 10 minutes. Sample tubes were placed on ice and E. coli tRNA (Roche, Basel, Switzerland) was added. The samples were mixed vigorously with chloroform and incubated for 3 minutes. The microcentrifuge tubes were centrifuged again at 4°C for 15 minutes (15,300 RCF). The clear aqueous phase was transferred to an RNase-free microcentrifuge tube. RNA was then precipitated in isopropanol and centrifuged for 4°C for 10 minutes. The pellet was washed in 75% ethanol, 100% ethanol, and resuspended in Diethyl Pyrocarbonate-treated distilled and deionized water (DEPC ddH 2 0). Samples were stored at Ϫ80°C. RNA was also extracted from an EBV-positive testicular lymphoma to serve as a positive control.
A one-tube reverse-transcription/cDNA amplification method followed by a nested cDNA PCR amplification was used. Nested primers (5'-ATCTTCGGGTGCTTACTTG-3' external sense, 5'-AAGGCCAAAAGCTGCCAGATGGTGGC-3' external anti-sense, 5'-CATTGTTCCTTGGAATTGTGCTGT-TC-3' internal sense, and a 5'-ACCAAGTCGC-CAGAGCATC-3' internal anti-sense) were designed to span an intron in the EBV genome, so amplification of cDNA would yield a different size band than amplification of genomic DNA.
An initial PCR reaction mix of 0.2 mM DNTPs, 1X PCR buffer (Promega, Madison, WI), 1.4 mM MgCl 2 , 10 ng/l sense and anti-sense LMP-1 primers, and DEPC ddH 2 0 was made. Before each reaction, 2.5 U/rxn Taq polymerase (Promega), 12.5 U/rxn Reverse Transcriptase AMV (Roche), 40 U/rxn RNase Inhibitor (Roche) were combined with the initial PCR reaction mix. This final reaction mix was then aliquoted to individual reaction tubes and sample RNA was added. The solution was then cycled through the following steps: a reverse transcription at 42°C (30 minutes), denaturation at 95°C (4 minutes), and 35 cycles of 95°C (1 minute), 57°C (2 minutes), 72°C (2min), followed by a final extension of 72°C (7 minutes). After completion of the RT-PCR reaction, 5l of cDNA product was used in a nested PCR reaction with internal primers. They were then cycled through the same program as previously described for the tubulin PCR reactions. Products were separated on a 2.5% agarose gel and visualized with ethidium bromide under UV light.
Immunohistochemistry
A DAKO LSAB2 HRP (DAB) staining kit was used for LMP-1 immunohistochemistry (IHC). Samples were analyzed with primary mouse monoclonal antibodies recognizing four distinct LMP-1 epitopes (DAKO) according to the manufacturer's instructions. Paraffin embedded sections were first deparaffinized twice in xylene for 5 minutes, then rehydrated for 3 minutes in absolute ethanol twice and 95% ethanol twice. Sections were pretreated with pronase (DAKO) to break down formalincrosslinking. The samples were counterstained in Mayer's Haemtatoxylin (DAKO) for 5 minutes and dipped 10 times into 37 mM ammonia. Slides were then treated with aqueous crystal mounting medium (Biomeda) and coverslipped with Permount (Fisher). Sections from a paraffin-embedded EBVpositive hu-PBL-SCID lymphoma were stained as positive controls. Appropriate negative controls were used in each run. Table 1 summarizes the clinicopathologic information. All patients were women, ages 21 to 65 at the time of diagnosis. Examination of hematoxylin and eosin stained sections revealed that 19 of the 20 tumors were fibroadenomas with classic histologic features of elongated and attenuated ducts, compressed by a fibrous proliferating stroma ( Fig. 2A  and B) . The single case of carcinoma was an invasive ductal carcinoma with associated ductal carcinoma in situ. None of the cases had prominent lymphocytic infiltrates.
RESULTS
Clinical Findings and Histologic Study
Detection of EBV-Specific Sequences and Protein
Thirteen of the 18 (72%) fibroadenomas were positive for EBER-2 sequence (Table 1, Fig. 1 ). Amplification of the tubulin gene confirmed that the DNA was suitable for PCR amplification. EBER-2 DNA sequence was successfully amplified from the extracted DNA of a paraffin-embedded EBVpositive testicular lymphoma. The water control (in which no sample DNA was added) did not yield a product, indicating the reaction was free of contamination, an important concern in this experiment. Fourteen tumors were analyzed by nested RT-PCR for LMP-1 RNA. RNA extracted from an EBVpositive testicular lymphoma was amplified simultaneously with the samples, controlling for the RNA extraction technique, PCR conditions, and reagents. The primers were designed to target an intron sequence to yield an expected product of 258-bp. In contrast, amplification of LMP-1 DNA contamination was expected to produce a 333-bp product, and thus, easily recognized. Although the testicular lymphoma consistently displayed the expected RNA band, none of the breast fibroadenoma samples showed evidence of LMP-1 RNA, likely due to minute yields of this RNA species.
All 20 tumors from immunocompromised patients and 11 tumors from non-immunocompromised patients were immunohistochemically stained with antibodies for LMP-1. Results were scored independently by two investigators. The hu-PBL-SCID lymphoma control consistently displayed strong staining of the EBV-transformed human lymphocytes. As expected, surrounding mouse tissue did not stain positively for LMP-1. Twelve fibroadenomas from immunocompromised patients (60%) expressed LMP-1 protein in the cytoplasm of the epithelial cells (Fig. 2) . The single case of invasive ductal carcinoma was negative for LMP-1.
All fibroadenomas from nonimmunocompromised patients were negative (Fisher's exact test, P ϭ .0006). Adipocytes, normal breast lobules and stromal cells were negative in all cases. Table 1 summarizes the results of EBER-2 PCR, LMP-1 RT-PCR, and LMP-1 immunohistochemistry.
DISCUSSION
Although the correlation between EBV and lymphoproliferative disorders is strongest, EBV has also been associated with several cancers of epithelial origin, such as nasopharyngeal carcinoma and gastric carcinoma (1, 2, 9 ). In addition, EBV has long been suspected to play a role in human breast carcinogenesis. The presence of a mouse mammary tumor virus in rodents and published reports of HIV-positive rapidly growing breast cancers suggest a possible viral etiology for some breast cancers (10, 16) . One study reported multiple and bilateral fibroadenomas in immunosuppressed patients receiving cyclosporin A (17) . Isolated studies have investigated the EBV/breast cancer association with contradictory results (2, 18, 19) . This is the first study to investigate the role of EBV in rapidly growing breast tumors in immunocompromised patients. We detected the EBV genome, through PCR amplification of EBER-2 DNA, in 13 of 18 (72%) tumors (Fig. 1) , and LMP-1 protein in 12 of 20 (60%) (Fig. 2) of the tumors studied. The fact that none of the tumors had lymphocytic infiltration minimizes the possibility that the positive EBER-2 results were due to contaminating lymphocytes. Nine tumors (45%) were concordantly positive for both, EBER-2 DNA and LMP-1 protein.
None of the fibroadenomas from nonimmunosuppressed patients expressed LMP-1 protein (Fisher's exact test P ϭ .0006). Therefore, we conservatively estimate that EBV is associated with the development of fibroadenomas in immunocompromised patients in 45% of the cases but not in non-immunocompromised patients. We did not, however, detect LMP-1 RNA in our samples using nested RT-PCR. This was likely due to the low sensitivity of our assay and the paucity of RNA material extracted from tumor sections. Although our protocol was developed from several published reports of RNA isolation from paraffin embedded tissues, we were unsuccessful in determining whether our extracted RNA was technically suitable for PCR and thus, we were unable to replicate in our samples previously published results (20) . The projected yield of RNA for each sample was so marginal that co-amplification of tubulin RNA would have jeopardized the RT-PCR of LMP-1 RNA. It is also possible that levels of LMP-1 message are too low in fibroadenomas to be detected through RT-PCT, yet are sufficient to translate proteins and participate in the pathogenesis of fibroadenomas.
We have established for the first time an association between EBV infection and fibroadenomas of the breast in immunosuppressed patients. The mechanism by which EBV may be implicated in breast tumorigenesis has not been elucidated. It appears from the epidemiologic literature that EBV infection alone is not sufficient for breast tumor development in humans. This assertion is consistent with the existence of EBV-positive benign breast tumors. In this study, we localized EBV to epithelial cells within tumor samples. It is possible, that EBV converts the epithelial cells to a preneo- Although we did not set out specifically to do so, our results may help reconcile some of the conflicting results from previous studies that investigated EBV in breast tumors. Among our samples, a significant proportion (72 %) were positive by at least one technique (EBER-2 PCR). In the Bonnet (2) and Labreque (18) studies, in which they demonstrated the presence of EBV genome using PCR, only a handful of samples were analyzed by another EBV detection technique such as IHC. In the negative studies of Chu et al. (22, 23) and Glasser et al. (19) , EBER-2 PCR amplification was not performed. Our results show that different EBV detection techniques often display seemingly contradictory results, possibly because their sensitivity depends on sample-specific preparation at the time of fixation, or subsequent alterations of the specimens over time. The difference between previous studies showing positive and negative associations between EBV and breast cancer may be due to choice and number of detection modalities. Therefore, although EBV-mediated breast cancers may have different patterns of EBV-specific gene expression than EBV-mediated fibroadenomas, our data suggest that future studies of this kind should involve at least two EBV screening approaches to confirm potential associations.
In conclusion, we have demonstrated that EBV is specifically present in the epithelial cells of a welldefined subset of breast tumors. This is the first study to show the association between EBV and benign breast neoplasms. Furthermore, the localization of EBV exclusively in the tumor epithelial cells suggests that EBV may play a causative role in the development of breast fibroadenomas in immunosuppressed patients.
